$APRE If phase 3 resembles phase 2 in strenght this will go +60 imo. And since the design of their phase 3 is very similar to phase 2, I don´t see any reason the results should not be as stellar. If you heard the two doctors attending the latest Baird conference call, they had a hard time hiding their enthusiasm. And they both have patients in the study. To me this looks like a real winner here.